Omfiloctocog Alfa Biosimilar Recombinant Protein (Factor VIII) for Research
Cat No.: GMP-Bios-INN-934
Pre-Made Omfiloctocog Alfa Biosimilar, Recombinant Protein targeting F8: Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Omfiloctocog alfa is the first third-generation B-domain-deleted recombinant factor VIII. It is used to treat the hemophilia A
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-934-1mg | 1mg | 3090 |
| GMP-Bios-INN-934-10mg | 10mg | |
| GMP-Bios-INN-934-100mg | 100mg | |
| GMP-Bios-INN-934-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Omfiloctocog Alfa Biosimilar, Recombinant Protein targeting F8: Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E |
| INN Name | Omfiloctocog Alfa |
| Target | F8 |
| Format | Recombinant Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | F8 (coagulation factor VIII) with deleted B-domain |
| VD LC | F8 (coagulation factor VIII) with deleted B-domain |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Sinocelltech Ltd. (Beijing China) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |

